Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.33 |
| ▸ | PDE7B | Q9NP56 | 1/20 | 0.33 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.32 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.32 |
| ▸ | GOT1 | P17174 | 1/20 | 0.32 |
| ▸ | KHK | P50053 | 1/20 | 0.30 |
| ▸ | CASP1 | P29466 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30170698 | 0.75 | AHR (0.41) | TDP1GOT1 | |
| SCHEMBL28775497 | 0.74 | FLT1 (0.36) | — | |
| SCHEMBL1102314 | 0.74 | ALDH1A1 (0.40) | GOT1 | |
| SCHEMBL30040980 | 0.74 | ALDH1A1 (0.40) | GOT1 | |
| SCHEMBL23526206 | 0.73 | KDM1A (0.31) | — | |
| SCHEMBL25546700 | 0.71 | ALDH1A1 (0.36) | TDP1GOT1 | |
| SCHEMBL13197707 | 0.69 | HPRT1 (0.39) | PDE7APDE7B | |
| SCHEMBL23932248 | 0.69 | — | — | |
| SCHEMBL3601771 | 0.67 | PDE5A (0.42) | GOT1 | |
| SCHEMBL8423973 | 0.67 | MAPT (0.45) | TDP1GOT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250215004-A1 | AZOLO COMPOUNDS FOR TREATMENT OF FIBROTIC DISEASES | GEORG-AUGUST-UNIVERSITAET GOETTINGEN STIFTUNG OEFFENTLICHEN RECHTS (DE) | 2025-07-03 | — | — | US | disclosed |
| EP-4559521-A2 | AZOLO COMPOUNDS FOR TREATMENT OF FIBROTIC DISEASES | Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts, Universitätsmedizin (DE) | 2025-05-28 | — | — | EP | disclosed |
| EP-4404931-B1 | AZOLO COMPOUNDS FOR TREATMENT OF FIBROTIC DISEASES | GEORG AUGUST UNIV GOETTINGEN STIFTUNG OEFFENTLICHEN RECHTS UNIVSMEDIZIN (DE) | 2025-04-09 | — | — | EP | disclosed |
| EP-4458358-A1 | PYRIDAZINE COMPOUNDS FOR ANTIFIBROTIC THERAPY | Tietze Chemical Consulting UG (DE) | 2024-11-06 | — | — | EP | disclosed |
| EP-4404931-A1 | AZOLO COMPOUNDS FOR TREATMENT OF FIBROTIC DISEASES | Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts, Universitätsmedizin (DE) | 2024-07-31 | — | — | EP | disclosed |
| WO-2023222865-A1 | AZOLO COMPOUNDS FOR TREATMENT OF FIBROTIC DISEASES | GEORG-AUGUST-UNIVERSITÄT GÖTTINGEN STIFTUNG ÖFFENTLICHEN RECHTS, UNIVERSITÄTSMEDIZIN (DE) | 2023-11-23 | — | — | WO | disclosed |
| US-9242961-B2 | Aurora kinase modulators and method of use | AMGEN INC. (US) | 2016-01-26 | — | — | US | disclosed |
| EP-1984353-B1 | AURORA KINASE MODULATORS AND METHOD OF USE | AMGEN INC (US) | 2015-12-30 | — | — | EP | disclosed |
| EP-2418209-B1 | AURORA KINASE MODULATORS AND METHOD OF USE | AMGEN INC (US) | 2014-06-25 | — | — | EP | disclosed |
| US-20140066430-A1 | AURORA KINASE MODULATORS AND METHOD OF USE | AMGEN INC. (US) | 2014-03-06 | — | — | US | disclosed |
| EP-2418209-A1 | Aurora kinase modulators and method of use | Amgen Inc. (US) | 2012-02-15 | — | — | EP | disclosed |
| US-20110263530-A1 | Aurora Kinase Modulators and Method of Use | AMGEN INC. (US) | 2011-10-27 | — | — | US | disclosed |
| US-8022221-B2 | Aurora kinase modulators and method of use | AMGEN INC. (US) | 2011-09-20 | — | — | US | disclosed |
| US-7560551-B2 | Aurora kinase modulators and method of use | AMGEN INC. (US) | 2009-07-14 | — | — | US | disclosed |
| US-20090163501-A1 | Aurora kinase modulators and method of use | AMGEN INC. (US) | 2009-06-25 | — | — | US | disclosed |
| EP-1984353-A1 | AURORA KINASE MODULATORS AND METHOD OF USE | Amgen, Inc (US) | 2008-10-29 | — | — | EP | disclosed |
| US-20070185111-A1 | Aurora kinase modulators and method of use | AMGEN INC. | 2007-08-09 | — | — | US | disclosed |
| WO-2007087276-A1 | AURORA KINASE MODULATORS AND METHOD OF USE | AMGEN INC. (US) | 2007-08-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140066430-A1 | AURORA KINASE MODULATORS AND METHOD OF USE | AURKC, AURKA, AURKB | TDP1 1111/4885PDE7A 2002/4885PDE7B 2272/4885 |
| US-20070185111-A1 | Aurora kinase modulators and method of use | AURKC, AURKA, CDK1 | TDP1 1179/4885PDE7A 2881/4885PDE7B 2891/4885 |
| US-20250215004-A1 | AZOLO COMPOUNDS FOR TREATMENT OF FIBROTIC DISEASES | COL1A1, COL14A1, COL2A1 | TDP1 3272/4885PDE7A 1532/4885PDE7B 313/4885 |
| US-20110263530-A1 | Aurora Kinase Modulators and Method of Use | AURKC, AURKA, AURKB | TDP1 1111/4885PDE7A 2002/4885PDE7B 2272/4885 |
| US-20090163501-A1 | Aurora kinase modulators and method of use | AURKC, AURKA, AURKB | TDP1 1111/4885PDE7A 2002/4885PDE7B 2272/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.